1625 results about "Antiviral drug" patented technology

The invention provides novel nucleoside compounds of formula I wherein R¹, R^2a, R^2b, R³, R⁴, R⁵, R⁶, R^8a, R⁹ and R¹⁰ are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated diseases with compounds of formula I and pharmaceutical compositions comprising these compounds,

The present invention relates to compounds of formula I:

or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

The present disclosure relates to novel compounds of formulas (1) through (19) and to a method for treating humans infected with a virus including various respiratory viruses such as members of the Paramyxoviridae family (respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human parainfluenza virus (HPIV), measles virus, and mumps virus) with a compound of formulas (1) through (19). The present disclosure also relates to a cytopathic effect (CPE)-based assay that will assess virus-induced CPE for screening of compounds for treating viral diseases or inhibiting a virus.

The invention relates to pyrrolopyrimidine compounds as TLR7 agonists, and particularly relates to compounds of the formula (I) or pharmaceutically acceptable salts thereof, a preparing method of the compounds, pharmaceutical compositions containing the compounds or the salts, and uses of the compounds or the salts for preparation of antivirus medicines. The formula (I) is shown in the specification.

Novel antiviral combinations for the treatment or prevention of viral infections, in particular, HIV, are disclosed. This new antiviral therapy employs either DP-178 or DP-107, viral fusion inhibitors, in combination with at least one other antiviral therapeutic agent. The combinations of the invention are better than single therapies alone, and in certain cases are synergistic. The use of DP-178 or DP-107 is an ideal therapy to combine with another antiviral, given both the novel mechanism which this therapeutic blocks HIV transmission and the non-toxicity of the therapeutic.

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

A compound of formula (I) and pharmaceutically acceptable salts thereof; compositions containing it and its use in medicine, particularly for the treatment or inhibition of HCV infections, and processes for making it are disclosed.

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever and Crimean-Congo hemorrhagic fever).

The present invention relates to taste-masked oral formulations of influenza antivirals. The taste-masked pharmaceutical formulations for oral administration comprise one or more influenza antivirals, at least one taste-masking agent and at least one pharmaceutically acceptable excipient. Further, the taste-masked influenza antiviral formulations of the present invention are provided in the form of dispersible tablets, effervescent tablets, orally disintegrating tablets, chewable tablets, bite-dispersion tablets or the like, wherein the bitter taste of influenza antivirals is masked thereby providing palatable formulations.

The invention discloses a polyose nanometer material possessing antibiotic function and preparing method and application, which comprises the following steps: choosing water-soluble polyose material incorporating carboxy group or sulfonic group as basis material; loading metallic ion possessing bacterial inhibition active in water solution; setting metallic ion load capacity at 10-500mg/g and bacterial inhibition active at 99.9%; centrifugal separating; ultrasonic dispersing; freezing or spraying; drying; getting end product with particle diameter at 20-800nm. This invention can be used to textile industry, animal husbandry and medicine domain as antiviral drug.

The present invention relates to drug discovery methods, particularly antiviral drug discovery methods.

A method for the prophylaxis or treatment of an inflammatory bowel disease is provided, comprising administering to a patient having or at risk of developing an inflammatory bowel disease a therapeutically or preventatively effective amount of one or more antivirals selected from the group consisting of an antiviral active against herpes viruses, pharmaceutically acceptable salts thereof, and mixtures thereof, excluding anti-inflammatory agents selected from the group consisting of salicylates and salicylates prodrugs. The antiviral may be used in combination with additional active agents effective against inflammatory bowel disease.

The invention relates to a method for preparing an antiviral medicinal entecavir intermediate compound with a formula I. An oxidation system formed by TEMPO and iodine under an alkali condition is adopted to oxidize a compound with a formula III to obtain a compound with a formula II, and methylenation is carried out on the formula II by a methylenation system formed by titanium tetrachloride, magnesium, methylene chloride and tetrahydrofuran to obtain the compound with the formula I. The invention has easy acquirement of raw materials and simple and convenient method and is suitable for industrialized production.

The invention discloses a new process for sysnthesizing tenofovir disoproxil fumarate as an antiviral medicament. The invention greatly reforms the preparation process of tenofovir disoproxil as a keyintermediate for synthesizing the tenofovir disoproxil fumarate and establishes a new process suitable for industrial production. The new process includes the following steps: firstly (R)-methyl lactate and diisopropyl-p-ethyl methyl-phosphonate are condensed so that diisopropyl oxygroup- phosphonyl-methyl is introduced and the condensate can be used as a protection group of hydroxyl, and then the reaction step is shortened; secondly, carboxylic ester can be selectively reduced into alcohol by NaBH4 without affecting the phosphonate; and thirdly, adenine and 2-O-( diisopropyl oxygroup- phosphonyl-methyl)-(R)- isopropyl p-toluenesulfonic acid are condensed. Through hydrolysis, the enofovir disoproxil (II) as the key intermediate can be conveniently obtained, and the optical purity can reach more than 98%.

An animal-derived lipid is disclosed that is useful as a carrying agent for anti-microbial formulations. Pharmaceutical and other preparations including Emu Oil are also described as profoundly useful components in anti-bacterial, anti-fungal, and anti-viral treatments. This lipid material is extracted from the Emu (Dromais Novae-Hollandiae), an indigenous bird of Australia and New Zealand. The present invention also discloses therapeutic compositions comprising Emu Oil in combination with an extracellular product of Bacillus coagulans or Pseudomonas lindbergii strain, comprising a supernatant or filtrate of said culture suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. Additionally, the aforementioned therapeutic composition may also include an anti-microbial, anti-mycotic, and/or anti-viral agent. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions comprising Emu Oil in combination with an extracellular product of Bacillus coagulans or Pseudomonas lindbergii strain suitable for topical application to the skin or mucosal membranes of a mammal. Similarly, the aforementioned method may also employ a therapeutic composition additionally containing an anti-microbial, anti-mycotic, and/or anti-viral agent.

The invention relates to anti viral agents comprised of viral fusion inhibitors and at least a portion of an immunoglobulin constant region. The invention further relates to anti viral agents comprised HIV viral fusion inhibitors and an Fc fragment of an immunoglobulin. The invention also relates to methods of treating a viral infection, including HIV infection.

The invention relates to an inhalation spray of antivirus medicines. The inhalation spray comprises the following components in percentage by mass of 0%-30% of antivirus activity agents, 0%-30% of auxiliary agents, 0%-30% of taste masking agents and the balance solvents, wherein the content of the antivirus activity agents and the content of the auxiliary agents are not 0% at the same time. Compared with the prior art, the inhalation spray disclosed by the application has the purpose that during outbreak period of epidemic corona viruses and other viruses, people do not need to occupy medicalresources in short supply and only need to inhale the antivirus medicines into respiratory tracts, medicine administration is accurately targeted, and the objective of preventing virus infection and propagation can be achieved; in addition, through united medication of the antivirus activity agents and the auxiliary agents, besides, various medicines are inhaled into the respiratory tract of a patient, synergistic treatment effects are generated, the viruses are eliminated, and serious respiratory tract and infection and serious pulmonary infection caused by the viruses can be treated; and chloroquine type antivirus medicines and macrocyclic antibiotics are inhaled through spraying for united medication, and the dosage of the medicines can be notably reduced, so that side effects of prolonged QT intervals, Tdp and sudden cardiac death caused by the medicines can be reduced.

A pharmaceutical acceptable composition is provided. The composition comprises an effective amount of a non-steroidal anti-inflammatory drug (NSAID), a local anesthetic, and an antiviral drug.

The invention relates to an isoquinoline compound shown as a formula (A) or a stereoisomer, a pharmaceutically acceptable salt, a hydrate, a solvate or a crystal thereof, a medicinal composition thereof and application thereof as antiviral medicines. The isoquinoline compound inhibits hepatitis B DNA activity and hepatitis B surface antigen activity at the same time. The invention particularly relates to application thereof to preparation of medicines for treating and/or preventing hepatitis B, hepatitis B viruses (HBV) thereof and other viral infectious diseases, in particular to treatment and/or prevention of the hepatitis B and the hepatitis B viruses as HBV Surface antigen inhibitor medicines and HBV DNA production inhibitor medicines.

The invention discloses a method for preparing a compound shown as the formula (I), which is characterized by comprising the following steps of: (1) carrying out hydroxyl protection on a compound shown as the formula (II) by using a first hydroxyl protecting group, and then, reacting with hydride to generate a compound shown as the formula (III); (2) carrying out hydroxyl protection on the compound shown as the formula (III) by using a second hydroxyl protecting group, and then, removing the first hydroxyl protecting group to obtain a compound shown as the formula (IV); (3) enabling the compound shown as the formula (IV) to carry out non-corresponding selective epoxidation reaction to generate a compound shown as the formula (V); (4) reacting the compound shown as the formula (V) with thecompound shown as the formula (VI) in a polar aprotic solvent to obtain a compound shown as the formula (VII); and (5) carrying out condensation, desilylation and oxidization on the compound shown asthe formula (VII) to generate the compound shown as the formula (I). In the general formulas of the compounds in each step, R1 is selected from naphthyl or any substituted naphthyl; R2 is selected from alkyl or benzyl of C1-C4; P is selected from hydroxyl protecting groups, such as 2-methoxyl propyl or p-methoxyl benzyl and the like; P' is a hydroxyl protecting group capable of resisting and removing P, such as benzyl; and X is selected from Cl, Br, I or benzyloxyl.